Vivalis and Intercell have agreed to the terms of a merger to create a new European biotechnology company called Valneva that will specialize in vaccines and antibodies. Vivalis and Intercell have ...
Vivalis annonce qu'un brevet très important couvrant la plate-forme EBx a été délivré en Europe et en Australie.L'Office Européen des Brevets, et l'Office Australien des Brevets ...
VIVALIS (Euronext Paris : VLS), société biopharmaceutique qui fournit à l′industrie pharmaceutique des solutions innovantes basées sur des lignées cellulaires pour la production de vaccins et de ...
PARIS, Nov 24 (Reuters) - French biotech firm Vivalis and British partner GlaxoSmithKline have won U.S. clearance to begin testing on humans for the first time flu vaccines which were produced using ...
LONDON/PARIS (Reuters) - France's Vivalis and Austrian vaccine specialist Intercell are linking up in a rare cross-border deal that shows the need for Europe's fledgling biotech companies to grow in ...
Vivalis shareholders will own 55% of Valneva, with Intercell’s shares being converted at a 39% premium to the pre-deal share prices. An extra 8.6m shares will be issued to former Intercell ...
Die Gegenleistung aus dem Merger entspricht laut Mitteilung einem Aufschlag für Intercell Aktionäre von 38,5 Prozent auf Basis der letzten Schlusskurse. An der Wiener Börse notierten Intercell-Aktien ...
Companies will collaborate on antibody discovery against multiple targets. Vaccines company Sanofi Pasteur is paying Vivalis €3 million up front for exclusive access to the latter’s Humalex® platform ...
Firm is developing VLP-based vaccines. Vivalis has granted Novavax the right to use its EB66® cell line for the production of VLP-based vaccines against several new potential viruses. The EB66 cell ...
La société biopharmaceutique nantaise Vivalis vient de signer un accord de licence de recherche avec Merck Animal Health pour évaluer la production de vaccins vétérinaires supplémentaires sur la ...
Vivalis vient d’annoncer que le Chemo-Sero-Therapeutic Research Institute (Kaketsuken) a obtenu du Ministère Japonais de l’Agriculture, de la Forêt et de la Pêche, une autorisation de mise sur le ...
Valneva SE announces the completion of the merger of equals between Vivalis and Intercell, creating a new European biotech company focusing on vaccines and antibodies, striving to become a leader in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results